Clinical Trials · NCT05202353
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 30
- Start date
- Oct 2024
- Locations
- 1 site, Netherlands
- Primary endpoint
- Percentage of glucagon (GCG) receptors occupancy in the liver using Positron emission tomography (PET) imaging at End of Treatment (EOT) visit